BIO to hold Twelfth Annual BIO CEO and Investor Conference.
Share:
Press Release Summary:
BIO has announced plenary sessions and roundtables for Twelfth Annual BIO CEO & Investor Conference, to take place February 8-9, 2010, in New York City. Event will include opening plenary, What Lies Beneath Health Care Reform - The True Impact on Biotech, and closing plenary, The Unconventional Wisdom-Thoughts for a New Decade. Roundtable sessions will include M&A: Prospects for 2010, Capital Markets 360°, and others on alternative financing strategies and business development.
Original Press Release:
Twelfth Annual BIO CEO & Investor Conference Highlights Health Policy, M&A, Financing, Product Commercialization, Investment Outlook
WASHINGTON, D.C. - The Biotechnology Industry Organization (BIO) announces plenary sessions and roundtables planned for the Twelfth Annual BIO CEO & Investor Conference taking place February 8-9, 2010 at the Waldorf-Astoria Hotel in New York City.
"This year's lineup of business roundtable and plenary sessions reflect the unique needs and concerns of the life sciences industry in today's business environment," said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. "Many observers anticipate a greater number of financings, transactions and an increase in partnering activity in 2010. With that in mind, BIO has brought together the best minds in the industry, the investment community, and the political world to discuss the expectations for the new decade, the intersection of these areas, and how key leaders will be addressing challenges during this year and beyond."
The BIO CEO & Investor Conference's plenary sessions and business roundtables focus on economic and business issues facing the biotech industry, including health care policy, mergers and acquisitions, and product commercialization and financing, among other topics. Plenary sessions and roundtable topics include:
Opening Plenary: What Lies Beneath Health Care Reform - The True Impact on Biotech
Monday, Feb. 8, 4:30 p.m. - 5:30 p.m.
Alan Eisenberg, Executive Vice President for Emerging Companies & Business Development, BIO (moderator)
Panelists
Gary Andres, Vice Chairman of Public Policy and Research, Dutko Worldwide
Paul T. Kim, Partner, Foley Hoag, LLP
Michael Meehan, President, Blue Line Strategic Communications & Senior Vice President, Virilion, Inc.
Steve Usdin, Senior Editor, BioCentury
Closing Plenary: The Unconventional Wisdom-Thoughts for a New Decade
Tuesday, Feb. 9, 4:30 p.m. - 5:30 p.m.
George Milstein, Managing Director, Healthcare Mergers and Acquisitions, Wedbush PacGrow Life Sciences (moderator)
Panelists
o David Farhadi, M.D., Portfolio Manager, Fred Alger Management
o Rajiv Kaul, Portfolio Manager/Research Analyst, Fidelity Investments
o Dennis Purcell, Senior Managing Partner, Aisling Capital, LLC
o David Sable, M.D., Life Sciences Portfolio Manager, Special Situations Funds
o Nathan Sadeghi-Nejad, Director, Highside Capital Management
Roundtable: M&A: Prospects for 2010
Monday, Feb. 8, 12:00 p.m. - 1:00 p.m.
Christopher Wasden, Managing Director, Advisory Pharmaceutical and Life Sciences, PricewaterhouseCoopers (moderator)
Panelists
Tracy Lefteroff, Global Leader, Life Sciences Industry Services, PricewaterhouseCoopers
David A. Levin, Managing Director, Mergers & Acquisitions, Deutsche Bank Securities, Inc
Brent Saunders, Special Advisor, General Atlantic, Former, President, Global Consumer Health Care, Schering-Plough Corp
Stephen M. Simes, President & CEO, BioSante Pharmaceuticals, Inc.
Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co. Inc.
Roundtable: Capital Markets 360°
Monday, Feb. 8, 1:30 p.m. - 2:30 p.m.
Stephen Sands, Managing Director, Vice Chairman and Global Co-Head Healthcare Investment Banking, Lazard (moderator)
Panelists
Paul B. Cleveland, Chief Financial Officer & Executive Vice President, Corporate Development, Affymax, Inc.
Richard Gormley, Managing Director, Head of the Alternative Capital Finance Group, Lazard
David E. Kroin, Co-Founder, Managing Director, Great Point Partners
Graham Powis, Managing Director, Head of U.S. Equity Capital Markets, Lazard
Roundtable: Alternative Financing Strategies: Follow-Ons, PIPEs & Private Placements
Tuesday, Feb. 9, 10:30 a.m. - 11:30 a.m.
Joseph A. Smith, Partner, Corporate & Securities, WeinsteinSmith, LLP (moderator)
Panelists
Benjamin R. Bowen, Ph.D., Managing Director, Investment Banking, Rodman & Renshaw, LLC
Susanne S. Mulligan, Co-Head, Private Equity, Placements & PIPEs, Equity Capital Markets, Health Care Origination, Deutsche Bank Securities, Inc.
Matthew J. Pfeffer, Corporate Vice President and Chief Financial Officer, MannKind Corporation
Rajesh Shrotriya , M.D., Chairman, Chief Executive Officer and President, Spectrum Pharmaceuticals
H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences
Roundtable: Business Development: 4th & Goal - Are You Ready to Go Commercial?
Tuesday, Feb. 9, 12:00 p.m. - 1:00 p.m.
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance (moderator)
Panelists
Ron Cohen, M.D., President & Chief Executive Officer, Acorda Therapeutics
Mitchell H. Gold, M.D., President & Chief Executive Officer, Dendreon Corporation
Jay D. Kranzler, M.D., Ph.D, Chief Executive Officer & Chairman of the Board, Cypress Bioscience Inc.
John R. Leone, Partner, Paul Capital
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
Advance media registration is now available at
https://www.compusystems.com/servlet/ar?evt_uid=746&site=MEDIA.
The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. The meeting attracts institutional investors, industry analysts, and senior biotechnology executives. In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and mature biotechnology companies.
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsors, Citigroup, Deutsche Bank, Lazard and Roth Capital Partners.
Upcoming BIO Events
12th Annual BIO CEO & Investor Conference
February 8-9, 2010
New York, NY
9th Annual BIO Windhover & Pharmaceutical Strategic Outlook
February 23-25, 2010
New York City, NY
BIO-Europe Spring
March 8-10, 2010
Barcelona, Spain
BIO Intellectual Property Counsels Spring Conference and Committee Meeting
April 19-21, 2010
New Orleans, LA
Partnering for Global Health
May 3, 2010
Chicago, IL
McCormick Place Convention Center
BIO International Convention
May 3-6, 2010
Chicago, IL
McCormick Place Convention Center
2010 BIO Human Resources Conference
May 4-7, 2010
Chicago, IL
World Congress on Industrial Biotechnology and Bioprocessing
June 27-30, 2010
Washington, DC
BIO's Livestock Biotechnology Summit
September 28-30, 2010,
Sioux Falls, SD
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
